Results 51 to 60 of about 76,053 (241)
Advanced Science, EarlyView.Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley +1 more source
Pakistan Armed Forces Medical Journal, 2023 Objective: To determine the frequency of hand-foot syndrome and associated factors among patients receiving Capecitabine for the management of cancer in a tertiary care setting. Study Design: Cross-sectional study.
Ibtisam Idrees +5 more
doaj +1 more source
Current perspective - Trastuzumab [PDF]
, 2009 This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast ...
Cameron, D.A., Hall, P.S.
core +1 more source
Advanced Science, EarlyView.This work introduces a multimodal multi‐OoC platform that overcomes current limitations in liver‐tumor interaction studies and prodrug screening. By integrating dynamic microfluidic circuits, electrochemical sensing, and mass analysis, this platform enables non‐invasive, longitudinal monitoring of drug metabolism and hepatotoxicity, offering a ...
Dan Wang +10 more
wiley +1 more source
Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature [PDF]
, 2019 Drug-induced subacute cutaneous lupus erythematosus (SCLE) is the most common subtype of drug-induced systemic lupus erythematosus and has been associated with more than 100 drugs.
Marsch, Amanda F, Shakhbazova, Anastasia
core
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer [PDF]
, 2013 Background: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%.
Arnold, Dirk +9 more
core +1 more source
Annals of Gastroenterological Surgery, EarlyView.This systematic review and meta‐analysis evaluated the role of primary tumor resection (PTR) in asymptomatic patients with unresectable metastatic colorectal cancer. Across 17 eligible studies including 9317 patients, PTR did not improve overall or progression‐free survival compared with chemotherapy alone.
Junpei Takashima +3 more
wiley +1 more source
World Journal of Surgical Oncology, 2021 Background Capecitabine is a prodrug that is enzymatically converted to its active form, fluorouracil (also called 5-fluorouracil), which is commonly used as adjuvant chemotherapy in colorectal cancer patients. Severe gastrointestinal bleeding induced by
You Zou +3 more
doaj +1 more source
Adherence to Capecitabine Among Patients With Gastrointestinal Cancer: A Prospective Cohort Study
Acta Medica Iranica, 2023 Adherence to capecitabine, an effective oral chemotherapy agent, is essential in achieving treatment response in cancer. In this study, we aimed to investigate factors associated with non-adherence to capecitabine in a sample of patients with ...
Ahmad Khajeh-Mehrizi +6 more
doaj +1 more source
Duration of adjuvant chemotherapy for stage III colon cancer [PDF]
, 2018 BACKGROUND Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer.
Andre, Thierry +22 more
core +2 more sources